Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein-1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) can significantly improve the overall survival (OS) in cancer patients1. Here, CD274 is linked to cancer.